April 28 - June 1, 2006
Vol. 36, Issue 8
Back Issues
IN THIS ISSUE
'Living wage' debate
State of U
Tuition to increase
All aboard! the National LambdaRail
Researchers' treatment reverses Type 1 diabetes
Katherine Shirey wins award
Digest
Block scheduling
Great teachers
Uncovered cistern gives clues of early Lawn life
Commuting makes cents
Lowering barriers
Diversity post
Are your lights on?
Recycle

22nd Annual telethon set for June 3 and 4

Know anyone interested in working at U.Va.?
Lorna Sundberg International Center
Leading the way

 

Researchers’ treatment reverses Type 1 diabetes

Staff Report

Nadler
Dr. Jerry Nadler

Researchers at the University of Virginia Health System have reversed the course of newly acquired Type 1 diabetes in mice using a combined therapy of lisofylline and exendin-4. This treatment also helped the mice to return to and maintain normal, healthy levels of blood sugar. This is the first time that researchers have found a way to reverse diabetes by providing a combination treatment that also could help maintain normal levels of blood sugar in a mammalian model.

“This finding is very exciting, because it one day may provide an opportunity to restore insulin-producing cells in people with Type 1 diabetes without the need for toxic anti-rejection medications,” said Dr. Jerry Nadler, chief of the Division of Endocrinology and Metabolism.

Nadler and colleagues theorized that simultaneously blocking a biological pathway that damages beta cells in the pancreas, while adding a growth-promoting stimulus for beta cells, might provide the critical ability to reverse Type 1 diabetes.

The research team used two treatments, lisofylline (LSF) and exendin-4 (Ex-4), to reverse the course of diabetes in this model, according to their study, published online this month in Biochemical and Biophysical Research Communications. LSF suppresses certain immune cells that can destroy beta cells. It also allows beta cells to keep producing insulin, as they normally would, even in the presence of destructive substances called cytokines that cause inflammation. In response to glucose stimulation, LSF helps the beta cells to enhance their insulin secretion.

Ex-4 is a potent substance that increases insulin secretion and helps the beta cells to grow.

The study looked at nonobese diabetic mice divided into four groups that received either LSF alone, Ex-4 alone, the combination of LSF and Ex-4 or normal saline solution (no treatment at all). Soon after being diagnosed with diabetes through blood testing, the mice received one of the study treatments. Only the group receiving both study treatments was able to keep blood sugar levels in a normal range as measured by glucose tolerance tests. Interestingly, the group of mice receiving only LSF was able to stabilize blood sugar levels, but did not reduce those levels to a healthy, normal range. Ex-4 alone did not lead to improvements in blood sugar in these already diabetic mice, and mice receiving saline solution steadily had higher blood sugar levels.

The researchers are optimistic about these promising findings that a blocker of immune cell damage used with a beta-cell growth factor can control autoimmunity and even help restore beta cell function. “This treatment may someday benefit people with diabetes, because both LSF and Ex-4 have been tested in humans for other benefits and have been found to be safe,” Nadler said.

Type 1 diabetes represents 5 percent to 10 percent of all diabetes cases diagnosed, and in the United States there may be 2 million people with this form of diabetes.


CURRENT ISSUE

© Copyright 2006 by the Rector and Visitors
of the University of Virginia

UVa Home Page UVa Events Calendar Top News UVa Home Page